News

Despite high accuracy scores, the study found AI models often produce overly complex explanations, making them less effective for patient education.

The new indication adds to existing clearances for hemostasis and electrocoagulation.

Myron Czuczman, MD, of Citius Pharmaceuticals recently shared perspectives on the role and potential of Lymphir in CTCL.

The trial revealed that 40% of patients on izokibep achieved HiSCR75 by week 16, a notable improvement over the 20% on placebo.

The overall reduction of tumor size in all lesions treated in part 2 was approximately 86%.

Researchers suggested that itch control is key in reducing disease burden and improving life quality for patients with psoriasis and atopic dermatitis.

John Browning, MD, FAAD, FAAP, MBA, discusses the new online platform that allows young patients to share their skin journey with others.

Brenda Kong-Tunac, a patient with PsO, PsA, and skin of color, shares her experiences.

The study found 277 differentially expressed genes shared by RA and rosacea, opening up opportunities for treatment research.

Kindred spoke with Dermatology Times to discuss AbbVie's recent Science of Skin event and improving access to equitable dermatological care.

Galderma’s nemolizumab is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31.

To improve overall outcomes for patients with large basal cell carcinomas, it has been beneficial to employ the use of vismodegib as a neoadjuvant and/or adjuvant treatment.

A recent Australian study reviewed appropriate terminology, gender affirming options, and dermatological considerations in caring for gender-diverse patients.

This week’s collection of the latest dermatologic studies includes the impact of isotretinoin treatment on femoral cartilage thickness, cystic fibrosis dermatitis arthritis syndrome, the role of intratumoral therapies for cutaneous melanoma, and fractional pigment toning for treating benign epidermal pigmented lesions.

Jared Gollob, MD, shares highlights of Kymera Therapeutics' recent JID publication.

Sachin Shridharani, MD, FACS, discusses the READY-1 and READY-2 clinical trials and positive support for Relfydess.

Kristine Kucera, MPAS, PA-C, DHS, discusses her patient's challenging atopic dermatitis that was eventually cleared with upadacitinib.

Keep up with the latest headlines in dermatology from the past week, including the FDA's approval of Lymphir for CTCL, L'Oreal buying stake in Galderma, and more.

In case you missed it, this week we had news about the FDA approval of denileukin diftitox for relapsed or refractory cutaneous T-cell lymphoma, the initiated phase 3 trial of ESK-001 for plaque psoriasis, secukinumab for HS clusters, and more.

Researchers linked higher exposure to natural environments and green spaces with an increased risk of developing psoriasis.

Explore how surveyed providers perceive current and emerging therapies in the atopic dermatitis.

Researchers emphasized the need for improved reliability and regulatory frameworks for AI tools before they are integrated into dermatological practice.

Secukinumab improved outcomes in all clusters, with more frequent dosing benefiting severe cases.

Melasma, challenging due to varied pigmentation in different skin types, requires personalized, tailored care.

Increased COPD prevalence in patients with psoriasis likely reflects smoking correlation, according to researchers.

ND-ZnO technology also demonstrated substantial skin permeation and active ingredient delivery.

Rocco Serrao, MD, FAAD, reviewed a case study of a 20-year-old man with segmental vitiligo and the psychological impact of his vitiligo.

Follow-up results showed that 6 out of 9 patients achieved HiSCR at 3 months, with 5 maintaining this response at 6 months.

The approval is supported by positive phase 3 data for Lymphir in this indication.

Young patients are heading back to school, and common skin issues like acne, eczema, warts, and pigmentation can affect their confidence, Shanna Miranti, MPAS, PA-C, writes.